Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.410
+0.060 (4.44%)
Apr 15, 2026, 4:00 PM EDT - Market closed
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 1799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Shaun M. O'Neill M.B.A. | President and Chief Operating Officer |
| Michael Adam Gordon | General Counsel and Secretary |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Joseph Willis M.D. | Co-founder and Strategic Advisor |
| Dr. Amitabh Chak M.D. | Co-Founder and Strategic Advisor |
| Helen Moinova Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Matthew Riley | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | EFFECT | Notice of Effectiveness |
| Mar 26, 2026 | 424B5 | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 26, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 25, 2026 | 10-K | Annual Report |
| Feb 9, 2026 | SCHEDULE 13D/A | Filing |
| Dec 5, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 12, 2025 | 8-K | Current Report |